Table 5.

Future approaches to the pharmacotherapy of sickle cell disease.

  • Pharmacogenomics

  • Genotype patients to detect “high-risk” alleles for disease complications

    • KL, VCAM1, HLA, LDLR, TNF, IL4R, ADRB2 and CVA

    • NOS3 and ACS

    • BMP6, ANXA2, EDN1, TGFBR and AVN

    • PPH1, BMPR2, ACVRLK1, SLC6A4, PPARG and PH

    • CYP2D, OPRM1 and Opioid Response

  • Develop interactive networks of “high-risk” alleles

  • Develop novel therapeutics based on “global” high-risk alleles and “complication-specific” alleles

  • Genotype-based early identification and treatment of likely complications

 

  • Pharmacogenomics

  • Genotype patients to detect “high-risk” alleles for disease complications

    • KL, VCAM1, HLA, LDLR, TNF, IL4R, ADRB2 and CVA

    • NOS3 and ACS

    • BMP6, ANXA2, EDN1, TGFBR and AVN

    • PPH1, BMPR2, ACVRLK1, SLC6A4, PPARG and PH

    • CYP2D, OPRM1 and Opioid Response

  • Develop interactive networks of “high-risk” alleles

  • Develop novel therapeutics based on “global” high-risk alleles and “complication-specific” alleles

  • Genotype-based early identification and treatment of likely complications

 
View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal